Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Tempus has published a study in JAMA Network Open demonstrating the advantages of combining RNA and DNA sequencing in advanced non-small cell lung cancer (NSCLC) treatment. The retrospective study of over 5,500 NSCLC patients revealed that concurrent RNA- and DNA-based next-generation sequencing detected more actionable structural variants than DNA sequencing alone. 8.8% of patients showed at least one actionable variant, with the combined approach increasing variant detection by 15.3% and more than doubling the identification of rare structural variants compared to DNA sequencing alone.
Tempus ha pubblicato uno studio su JAMA Network Open che dimostra i vantaggi della combinazione di sequenziamento RNA e DNA nel trattamento del tumore polmonare non a piccole cellule (NSCLC) in fase avanzata. Lo studio retrospettivo su oltre 5.500 pazienti con NSCLC ha rivelato che il sequenziamento di nuova generazione basato su RNA e DNA ha rilevato più varianti strutturali azionabili rispetto al sequenziamento del solo DNA. 8,8% dei pazienti ha mostrato almeno una variante azionabile, con l'approccio combinato che ha aumentato la rilevazione delle varianti del 15,3% e più che raddoppiato l'identificazione di varianti strutturali rare rispetto al sequenziamento del solo DNA.
Tempus ha publicado un estudio en JAMA Network Open que demuestra las ventajas de combinar la secuenciación de RNA y DNA en el tratamiento del cáncer de pulmón no microcítico (NSCLC) avanzado. El estudio retrospectivo de más de 5,500 pacientes con NSCLC reveló que la secuenciación de próxima generación basada en RNA y DNA detectó más variantes estructurales accionables que la secuenciación de DNA sola. El 8.8% de los pacientes mostró al menos una variante accionable, con el enfoque combinado aumentando la detección de variantes en un 15.3% y más que duplicando la identificación de variantes estructurales raras en comparación con la secuenciación de DNA sola.
템퍼스는 JAMA Network Open에 연구를 발표하여 고급 비소세포 폐암(NSCLC) 치료에서 RNA 및 DNA 시퀀싱을 결합하는 이점을 보여주었습니다. 5,500명 이상의 NSCLC 환자를 대상으로 한 이 후향적 연구는 동시 RNA 및 DNA 기반 차세대 시퀀싱이 단독 DNA 시퀀싱보다 더 많은 실행 가능한 구조적 변이를 탐지했음을 밝혀냈습니다. 환자의 8.8%가 최소한 하나의 실행 가능한 변이를 보였으며, 결합된 접근 방식은 변이 탐지를 15.3% 증가시켰고 단독 DNA 시퀀싱에 비해 희귀 구조적 변이의 식별을 두 배 이상 증가시켰습니다.
Tempus a publié une étude dans JAMA Network Open démontrant les avantages de la combinaison du séquençage RNA et DNA dans le traitement du cancer du poumon non à petites cellules (NSCLC) avancé. L'étude rétrospective sur plus de 5 500 patients atteints de NSCLC a révélé que le séquençage de prochaine génération basé sur l'RNA et le DNA détectait plus de variantes structurelles exploitables que le séquençage du DNA seul. 8,8 % des patients ont montré au moins une variante exploitable, l'approche combinée augmentant la détection des variantes de 15,3 % et multipliant par plus de deux l'identification des variantes structurelles rares par rapport au séquençage du DNA seul.
Tempus hat eine Studie in JAMA Network Open veröffentlicht, die die Vorteile der Kombination von RNA- und DNA-Sequenzierung bei der Behandlung von fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) demonstriert. Die retrospektive Studie von über 5.500 NSCLC-Patienten ergab, dass die gleichzeitige RNA- und DNA-basierte Next-Generation-Sequenzierung mehr umsetzbare strukturelle Varianten als die DNA-Sequenzierung allein nachweisen konnte. 8,8% der Patienten wiesen mindestens eine umsetzbare Variante auf, wobei der kombinierte Ansatz die Variantenerkennung um 15,3% erhöhte und die Identifizierung seltener struktureller Varianten im Vergleich zur DNA-Sequenzierung allein mehr als verdoppelte.
- 15.3% increase in identifying patients with actionable variants using combined RNA/DNA sequencing
- Doubled detection rate of rare structural variants compared to DNA sequencing alone
- Study validates effectiveness of company's comprehensive genomic profiling approach
- None.
Insights
This research publication demonstrates significant clinical value in Tempus's dual RNA-DNA sequencing approach. The study's findings of a
- Enhanced detection capability could drive increased adoption of Tempus's testing platform in clinical settings
- Improved identification of rare structural variants strengthens Tempus's competitive position in precision oncology
- Data from 5,500+ patients provides robust evidence supporting the technology's clinical utility
The publication in JAMA Network Open, a prestigious peer-reviewed journal, validates Tempus's technological approach and could accelerate market penetration in the growing precision medicine market.
Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone. Specifically,
“This large study underscores the importance of using both RNA- and DNA-based comprehensive genomic profiling as a standard of care in advanced NSCLC, and more broadly in solid tumors," said Halla Nimeiri, MD, Chief Development Officer at Tempus. "By integrating RNA and DNA sequencing, we can detect a wider range of actionable alterations that might otherwise go undetected by DNA testing alone. This combined approach enhances clinicians' ability to provide more personalized treatment options for patients."
To read the full study, visit tempus.com/publications.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111944537/en/
Tempus Communications
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What were the key findings of Tempus (TEM) NSCLC study published in JAMA Network Open?
How many NSCLC patients were included in Tempus (TEM) 2024 research study?
What percentage of patients in Tempus (TEM) study showed actionable variants?
